PD-1抑制剂治疗结膜黑色素瘤5例
这项回顾性病例系列描述了5例转移性结膜黑色素瘤患者接受PD-1抑制剂治疗的情况。4例使用纳武利尤单抗者获得完全缓解,1例使用帕博利珠单抗者初期转移灶稳定但后进展。部分患者出现需停药的自身免疫性结肠炎。
要点
- 4例转移性结膜黑色素瘤患者经纳武利尤单抗治疗获完全缓解。
- 1例经帕博利珠单抗治疗初期稳定,11个月后进展换药。
- 2例纳武利尤单抗治疗者出现自身免疫性结肠炎需停药处理。
核心结论
- 抗PD-1治疗可用于转移性结膜黑色素瘤,长期无病生存需更久随访。
研究设计与样本
- 回顾性病例系列,纳入2013年3月6日至2017年7月7日接受免疫检查点抑制剂治疗的5例成人结膜黑色素瘤患者。
主要发现
- 5例转移性结膜黑色素瘤中4例女性、1例男性。
- 4例接受纳武利尤单抗者获完全缓解,完成治疗后1、7、9、36个月无疾病证据。
- 1例接受帕博利珠单抗者治疗前6个月转移灶稳定,后进展,11个月后停药换方案。
- 2例纳武利尤单抗治疗者发生自身免疫性结肠炎需停药,后续用全身皮质类固醇或英夫利西单抗处理。
临床怎么用
- 抗PD-1治疗可作为转移性结膜黑色素瘤的治疗选择,需监测免疫相关不良事件。
局限性
- 为病例系列,样本量小,需更长随访确定长期无病生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Conjunctival melanoma has the potential for regional lymphatic and distant metastasis. There is an urgent need for effective treatment for patients with metastatic or locally advanced conjunctival melanoma. OBJECTIVE: To describe the use of immune checkpoint inhibitors for the treatment of conjunctival melanoma in 5 adult patients. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review was conducted of the medical records of 5 patients with conjunctival melanoma who were treated with immune checkpoint inhibitors from March 6, 2013, to July 7, 2017. MAIN OUTCOMES AND MEASURES: Response to treatment and disease-free survival. RESULTS: Of the 5 patients (4 women and 1 man) with metastatic conjunctival melanoma, 4 were treated with a programmed cell death 1 (PD-1) inhibitor, nivolumab, and had a complete response to treatment with no evidence of disease at 1, 7, 9, and 36 months after completing treatment. One patient with metastatic conjunctival melanoma was treated with another PD-1 inhibitor, pembrolizumab, and had stable metastases during the first 6 months of treatment. Later disease progression resulted in treatment cessation after 11 months and switching to another therapy. Two patients treated with nivolumab developed autoimmune colitis that necessitated stopping the immunotherapy; these patients subsequently were managed with systemic corticosteroids or infliximab. CONCLUSIONS AND RELEVANCE: This case series report suggests that anti-PD-1 therapy can be used to treat metastatic conjunctival melanoma. Longer follow-up is needed to determine the long-term disease-free survival. Future studies might assess the potential for immune checkpoint inhibitors to obviate the need for orbital exenteration in selected patients with locally advanced disease.
引用
- Sagiv O, Thakar SD, Kandl TJ, et al. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma. JAMA Ophthalmol. 2018. PMID: 30352118. doi:10.1001/jamaophthalmol.2018.3488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。